Study: New drug prevents cytomegalovirus in stem cell transplant patients

09/25/2013 | Medscape (free registration)

A new oral antiviral drug that contains cidofovir proved effective in preventing cytomegalovirus infection in patients who had allogeneic hematopoietic cell transplants. A Phase II study published in the New England Journal of Medicine found that 10% of patients treated with CMX001 reported CMV incidence, compared with 37% in a placebo group.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX